Peptide Referee

DSIP: research, legal status and who sells it

DSIP (emideltide) is a nine-amino-acid peptide studied for its effects on sleep. In 2026, FDA's advisers voted against adding it to the compounding list.

By Editorial team. Updated Oct 14, 2026. Awaiting expert review

This page is information, not medical advice. DSIP is not approved as a medicine in the markets below unless stated. We don't publish dosing or usage instructions.

Also known as
Delta sleep-inducing peptide, Emideltide
Category
Nonapeptide studied for sleep
Evidence level
Early human trials
Price range
$1.78/mg to $14.00/mg, median $5.10/mg across 64 vendors (compare)
Our lab tests
None yet (how testing will work)
WhereStatus
United StatesNot FDA-approved; in July 2026 FDA's advisory committee voted 7–6 against adding emideltide to the 503A compounding list, in line with FDA staff's recommendation [1][2][3].
United KingdomNo UK-licensed medicine containing emideltide (DSIP) appears in the MHRA products database [4].
European UnionNo medicine containing emideltide (DSIP) is authorized in the EU, according to EMA's central and Article 57 product data [5][6].
CanadaNo product containing emideltide (DSIP) appears in Health Canada's Drug Product Database [7].
AustraliaDSIP is not named in Australia's Poisons Standard (October 2026) [8].
Sport (WADA)Not named on the 2026 Prohibited List; its section S0 bans any pharmacological substance with no current approval for human therapeutic use [9].
 Summaries of official sources, checked Oct 14, 2026. Rules change; follow the source links. Not legal advice.

What it is

Delta sleep-inducing peptide (DSIP), also called emideltide, is a nonapeptide reported to induce mainly slow-wave (delta) sleep in rabbits, rats, mice and humans [10][2].

Research status

The human evidence is old and small. A 1984 paper summarized small studies in which DSIP improved sleep in people with insomnia [11]. A 1984 review described effects on sleep, brain electrical activity, hormone levels and drug withdrawal in animals and some human studies, and noted that DSIP-like material had been detected in the brain, other organs and plasma of several mammals [10]. FDA’s 2026 review evaluated emideltide for opioid withdrawal, chronic insomnia and narcolepsy and concluded that the evaluation criteria weigh against adding it to the compounding list [2]. The same review cites a 2003 paper describing Deltaran, a mix of emideltide and glycine designed at a Russian Academy of Sciences institute, but FDA found that emideltide is not a registered drug in any country it searched [2].

Regulatory status

DSIP is not FDA-approved [1]. In July 2026, FDA’s advisory committee voted 7–6, with one abstention, against adding emideltide to the 503A compounding list; it was the only one of seven peptides the committee rejected [3][12]. No DSIP medicine is authorized in the UK, the EU or Canada [4][5][6][7]. It is not named in Australia’s Poisons Standard [8] or on WADA’s 2026 Prohibited List, although WADA’s section S0 bans substances with no current approval for human therapeutic use [9].

Quality and testing considerations

FDA has encountered multiple salts and derivatives sold under the same name [2], and its earlier safety review flagged possible immunogenicity and peptide-related impurities while noting that it had found no safety information for the proposed route of use [13]. A certificate of analysis should confirm identity by mass spectrometry and give a measured purity for the batch.

Where it’s sold

DSIP is sold online by research-chemical vendors; the tables below track listings.

DSIP prices: cheapest listings

The five lowest $/mg listings out of 89. See all DSIP prices

Vendor Transparency Product Size Price $/mg vs median Stock Vendor's page
Nexaph 45/100* DSIP 10mg (10 vials/kit) 10 mg × 10 $178 $1.78/mg −65% In stock View
IDUN Peptides 50/100* DSIP 10 mg × 10 $190 $1.90/mg −63% In stock View
Crush Research 10/100* DSIP 10mg 10 mg × 10 $199 $1.99/mg −61% In stock View
S1 Research 50/100 DSIP 10mg(9.65mg) 10 mg $22 $2.20/mg −57% In stock View
IDUN Peptides 50/100* DSIP 10 mg × 5 $120 $2.40/mg −53% In stock View

Prices come from each vendor's public product feed and were last fetched Oct 15, 2026. They exclude shipping and discounts. $/mg uses the labeled amount, not measured content. A transparency score marked * is based on fewer than six checks; checks we couldn't complete score 0. How we compare prices.

Sources

  1. Drugs@FDA: FDA-Approved Drugs (database searched by active ingredient). U.S. Food and Drug Administration. Accessed Oct 14, 2026
  2. FDA Briefing Document: Emideltide-Related Bulk Drug Substances, Pharmacy Compounding Advisory Committee, July 23-24, 2026. U.S. Food and Drug Administration. Accessed Oct 14, 2026
  3. FDA Panel Backs 6 Peptides for Compounding (31 July 2026). AJMC (The American Journal of Managed Care). Accessed Oct 14, 2026
  4. MHRA Products: licensed-medicine search for "emideltide". Medicines and Healthcare products Regulatory Agency (UK). Accessed Oct 14, 2026
  5. EMA medicines data: centrally authorised human medicines (export of 14 October 2026). European Medicines Agency. Accessed Oct 14, 2026
  6. EMA Article 57 product data: medicines authorised in the EU/EEA (data as of 9 October 2026). European Medicines Agency. Accessed Oct 14, 2026
  7. Drug Product Database online query (searched by active ingredient). Health Canada. Accessed Oct 14, 2026
  8. Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327, registered 30 September 2026). Federal Register of Legislation, Australian Government. Accessed Oct 14, 2026
  9. World Anti-Doping Code International Standard: Prohibited List 2026 (in force 1 January 2026). World Anti-Doping Agency. Accessed Oct 14, 2026
  10. Delta-sleep-inducing peptide (DSIP): a review. Neuroscience & Biobehavioral Reviews (1984). Accessed Oct 14, 2026
  11. DSIP in insomnia. European Neurology (1984). Accessed Oct 14, 2026
  12. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. U.S. Food and Drug Administration. Accessed Oct 14, 2026
  13. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 22 April 2026). U.S. Food and Drug Administration. Accessed Oct 14, 2026